Literature DB >> 28579265

Importance of chewing, saliva, and swallowing function in patients with advanced oral cancer undergoing preoperative chemoradiotherapy: a prospective study of quality of life.

D Nemeth1, L Zaleczna2, A Huremovic1, J Engelmann1, P W Poeschl3, M Strasz1, S Holawe1, G Kornek4, A Laskus5, C Sacher1, B M Erovic6, C Perisanidis7.   

Abstract

The primary objective of this study was to investigate the quality of life (QOL) of patients with oral squamous cell carcinoma (OSCC) undergoing curative neoadjuvant chemoradiotherapy followed by radical tumour resection and simultaneous oral cavity reconstruction, using two validated questionnaires. A secondary objective was to assess clinical variables predicting post-treatment dysfunction in chewing, saliva, and swallowing. Thirty-five patients with locally advanced OSCC who underwent preoperative chemoradiotherapy were recruited prospectively. All patients completed both the University of Washington Quality of Life version 4 questionnaire (UW-QOL) and the Functional Assessment of Cancer Therapy-Head & Neck version 4 questionnaire (FACT-H&N). UW-QOL and FACT-H&N items were associated with clinical variables. Nearly three-quarters of OSCC patients perceived good to excellent levels of overall QOL after preoperative chemoradiotherapy. Chewing difficulties, decreased salivary function, and swallowing dysfunction were the most frequent complaints of OSCC patients. Items related to food intake were significantly worse in OSCC patients older than 60 years and those with T4 tumours, as well as those without alcohol intake. Chewing, saliva, and swallowing are the most significant issues in patients with OSCC undergoing preoperative chemoradiotherapy. The results of this study may help guide treatment decisions for OSCC patients based on more accurate expectations of adverse effects of cancer treatment.
Copyright © 2017 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  mastication; neoadjuvant chemoradiotherapy; oral cancer; quality of life; saliva; swallowing

Mesh:

Year:  2017        PMID: 28579265     DOI: 10.1016/j.ijom.2017.05.005

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  5 in total

1.  A systematic review of validated tools assessing functional and aesthetic outcomes following fibula free flap reconstruction of the mandible.

Authors:  Ivana Petrovic; Hina Panchal; Paula Demetrio De Souza Franca; Marisol Hernandez; Colleen C McCarthy; Jatin P Shah
Journal:  Head Neck       Date:  2018-12-12       Impact factor: 3.147

2.  The course of swallowing problems in the first 2 years after diagnosis of head and neck cancer.

Authors:  Jorine A Vermaire; Cornelis P J Raaijmakers; Evelyn M Monninkhof; C René Leemans; Robert J Baatenburg de Jong; Robert P Takes; Irma M Verdonck-de Leeuw; Femke Jansen; Johannes A Langendijk; Chris H J Terhaard; Caroline M Speksnijder
Journal:  Support Care Cancer       Date:  2022-08-30       Impact factor: 3.359

3.  Perioperative symptom burden and its influencing factors in patients with oral cancer: A longitudinal study.

Authors:  Meijun Ou; Guifen Wang; Yixia Yan; Hong Chen; Xianghua Xu
Journal:  Asia Pac J Oncol Nurs       Date:  2022-04-23

4.  Survival-Weighted Health Profiles in Patients Treated for Advanced Oral Cavity Squamous Cell Carcinoma.

Authors:  Yao-Te Tsai; Wen-Cheng Chen; Cheng-Ming Hsu; Ming-Shao Tsai; Geng-He Chang; Yi-Chan Lee; Ethan I Huang; Chiung-Cheng Fang; Chia-Hsuan Lai
Journal:  Front Oncol       Date:  2021-09-29       Impact factor: 6.244

5.  Factors associated with masticatory function as measured with the Mixing Ability Test in patients with head and neck cancer before and after treatment: a prospective cohort study.

Authors:  Jorine A Vermaire; Cornelis P J Raaijmakers; Evelyn M Monninkhof; Irma M Verdonck-de Leeuw; Chris H J Terhaard; Caroline M Speksnijder
Journal:  Support Care Cancer       Date:  2022-02-01       Impact factor: 3.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.